Brief: Paion Says Hana Pharm Gets Market Approval For Byfavo In Procedural Sedation In South Korea
31/08/2021 08:33
Aug 31 (Reuters) - PAION AG PA8G.DE :
* HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO
(REMIMAZOLAM) IN
PROCEDURAL SEDATION IN SOUTH KOREA
Source text for Eikon: ID:nEQ5VY3b1a
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hana Pharm
See all newsBrief: Hana Pharm Co Ltd To Divest 23 Billion Won Worth Of Shares In Samjin Pharm
Brief: Hana Pharm To Invest 57 Billion Won In Building A New Factory In Pyeongtaek, South Korea
Brief: Hana Pharm Wins 57 Billion Won Order
Brief: Paion Says Hana Pharm Gets Market Approval For Byfavo In Procedural Sedation In South Korea
Brief: Paion - NDA Approval Of Byfavo In South Korea